The maker of the GLP-1 weight-loss drug Wegovy is promising “a lower, predictable monthly price” for patients who use a new subscription program for the medication. The savings add up to $600 a year ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Diabetes patients taking ...

Nation’s largest urgent care network to pilot medically supervised weight management services including potential use of GLP-1s American Family Care (AFC), the nation’s leading urgent care provider ...

A common refrain since GLP-1 weight-loss drugs hit the market is that the price of treatments has led many employers to hesitate about providing access to the drugs through company health plans. In ...

Hotel rewards programs are free and easy to join, but choosing the right one can make a meaningful difference in how far a traveler's budget stretches. Nearly every major hotel chain offers its own ...

A new study finds that certain patterns of AI use are driving cognitive fatigue, while others can help reduce burnout. by Julie Bedard, Matthew Kropp, Megan Hsu, Olivia T. Karaman, Jason Hawes and ...

Add Yahoo as a preferred source to see more of our stories on Google. With just one trip to the grocery store, you can buy staples to help you eat healthier. Greens, eggs, yogurt, popcorn, oats and ...

Even in a world where GLP-1 weight loss drugs seem like a miraculous weight loss solution, diet, exercise, and other healthy lifestyle changes are still needed to help people lose weight — and keep ...

Pentagon's OPEN program to help set China-free minerals prices Four critical minerals to be AI model's first focus Program aims to help offset Chinese market interference Questions on how tariffs ...

Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...